This article is educational and summarizes published research and news reports. It is not medical advice. Retatrutide, EloraTZP, CagriSema, and trevogrumab are investigational and not FDA-approved. Talk to your prescriber before making any medication decisions.
The 30-second answer
Most conversations about stopping Ozempic, Wegovy, Mounjaro, or Zepbound focus on one thing: weight regain. This study looked at something more serious. In people with type 2 diabetes, the heart protection built up while taking a GLP-1 medication appeared to fade quickly after stopping, and longer breaks were linked to higher risk.
Senior author Ziyad Al-Aly, MD, a clinical epidemiologist at WashU Medicine, summed it up: "When they stop, it's not just weight that comes back; they experience a resurgence in inflammation, blood pressure, and cholesterol. Weight regain is visible; the metabolic reversal is not" (ScienceDaily).
Why this question matters now
Stopping is common. About one in eight U.S. adults now uses a GLP-1 medication, and roughly half stop not long after starting, according to the WashU release. A separate Danish study in JAMA Network Open found that 49% of more than 157,000 first-time semaglutide users stopped within 12 months (Axios).
People stop for real reasons: cost, side effects, shortages, insurance changes, or simply feeling they have reached their goal. Al-Aly noted, "Many quit after a few months because of cost, side effects or shortages." Our earlier coverage of GLP-1 discontinuation data and what to do when an employer drops coverage covers many of those situations.
How the study worked
| Detail | BMJ Medicine study |
|---|---|
| Authors | Yan Xie, Taeyoung Choi, Ziyad Al-Aly (Washington University in St. Louis) |
| Data source | U.S. Department of Veterans Affairs health records |
| Participants | 333,687 veterans with type 2 diabetes |
| Groups | 132,551 prescribed GLP-1 medications; 201,136 prescribed sulfonylureas |
| Follow-up | Up to 3 years, with GLP-1 status reassessed every 6 months |
| Outcome | Major adverse cardiovascular events: heart attack, stroke, and death |
| Method | Target trial emulation (an observational design that mimics a clinical trial) |
Source: ScienceDaily / Washington University.
The comparison group took sulfonylureas, older diabetes pills such as glipizide (Glucotrol), glimepiride (Amaryl), and glyburide. These medications lower blood sugar but are not known for heart protection, which makes them a useful baseline.
During the study, 26% of GLP-1 users stopped completely, and about 23% had a gap of at least six months before restarting.
The key results
| Treatment pattern | Cardiovascular risk |
|---|---|
| Continuous GLP-1 for 3 years vs. sulfonylureas | 18% lower (about 4 fewer events per 100 people) |
| GLP-1 for 2.5 years, then stopped, vs. sulfonylureas | 15% lower |
| GLP-1 for 2 years, then stopped, vs. sulfonylureas | 7% lower |
| Stopped before 18 months vs. sulfonylureas | No significant benefit |
| Stopped and later restarted vs. sulfonylureas | 12% lower |
| Treatment gap before restarting vs. continuous use | 4% to 8% higher |
| 1 year off without restarting vs. continuous use | 14% higher |
| 2 years off vs. continuous use | 22% higher |
Source: ScienceDaily / Washington University. All figures are relative risk differences.
What the pattern shows
The message from the data is that heart protection appears to build slowly and disappear quickly. According to the release, spending just one year off medication was enough to lose benefits that had taken years of continuous treatment to build. And people who stopped before 18 months saw no meaningful heart benefit by the end of the study at all.
Restarting brought some protection back, but not all of it, which the researchers interpret as discontinuation leaving a lasting effect.
Why stopping might raise heart risk
The researchers describe it as "metabolic whiplash." While on a GLP-1 medication, several heart risk factors improve together: weight, blood pressure, cholesterol, blood sugar, and inflammation. When the medication stops, those improvements can reverse. "Our data suggest this metabolic whiplash is detrimental to heart health," Al-Aly said.
Other research points the same way. Axios summarized several recent studies (Axios):
- A review of more than 289,000 patients in Diabetes, Obesity and Metabolism found that stopping within the first year was linked to higher risks of coronary artery disease and heart failure, and that 60% to 90% of lost weight may return within a year.
- A review in Nature Reviews Endocrinology found that stopping commonly leads to rising blood sugar and loss of cardiovascular risk-factor improvements, and warned that repeated stop-and-start cycles could add long-term heart risk.
- A mouse study in Cell Reports found signs of an "obesity memory" in fat cells, which may help explain why the body tends to regain weight.
Important limits of this study
This is valuable research, but it has boundaries you should know about:
- It is observational. People who stop GLP-1 medications may differ from those who continue in ways the data cannot fully capture, such as getting sicker, losing insurance, or having other health changes. Target trial emulation reduces this bias but does not eliminate it.
- Everyone had type 2 diabetes. The results may not apply directly to people taking GLP-1s for weight loss alone.
- Veterans skew older and male. Results may differ in other groups.
- Relative risk is not absolute risk. A 22% higher relative risk means different things for a 45-year-old with no heart disease and a 70-year-old with a prior heart attack. Your prescriber can help you understand your personal baseline.
What this means if you are thinking about stopping
None of this means you can never stop a GLP-1 medication. It means stopping is a medical decision worth planning, not something to do abruptly or because a refill fell through. Here is a practical approach:
1. Talk to your prescriber first
Ask specifically about your cardiovascular risk and whether the benefits of continuing outweigh your reasons for stopping. Al-Aly urged health systems to have "candid conversations about the long-term nature of treatment."
2. Solve the reason, not just the symptom
- Side effects? A dose reduction or slower titration may help. See managing GLP-1 side effects.
- Cost? Manufacturer programs, Medicare options, and cash-pay pricing have changed a lot in 2026. See our Medicare GLP-1 Bridge guide and TrumpRx savings guide.
- Prefer a pill? Oral options now exist. See our Foundayo guide and oral vs. injectable comparison.
3. Avoid long gaps
The data suggest that even six-month gaps carry a cost. If you know a coverage change is coming, plan ahead with your care team to minimize time off.
4. If you do stop, keep the other levers strong
Monitor blood pressure, cholesterol, and A1C more closely in the months after stopping. Keep up protein intake and strength training to protect muscle. Our guide to stopping a GLP-1 safely walks through a tapering approach and what to watch for.
Questions to ask your prescriber
If you are considering stopping, pausing, or switching a GLP-1 medication, these questions can make the conversation more productive:
- What is my personal cardiovascular risk, and how much of my current protection likely comes from this medication?
- If cost is the problem, are there savings programs, lower-cost formulations, or alternative medications I qualify for?
- If side effects are the problem, can we lower the dose or slow down instead of stopping completely?
- If I do stop, which numbers should we check, and how often? (Blood pressure, A1C, cholesterol, and weight are common.)
- If I stop and want to restart later, do I need to begin again at the lowest dose?
Bringing your own records helps. A simple log of weight, doses, missed doses, and side effects over the past few months gives your prescriber a much clearer picture than memory alone.
Common reasons people stop, and alternatives to consider
| Reason for stopping | Options to discuss first |
|---|---|
| Nausea or stomach problems | Lower dose, slower titration, smaller meals, changing injection day timing |
| Cost or lost coverage | Manufacturer savings, cash-pay programs, Medicare options, switching to a covered medication |
| Supply problems | Switching to an equivalent available medication or dose rather than going without |
| Reached goal weight | Maintenance dosing at a lower level instead of stopping completely |
| Dislike of injections | Oral GLP-1 options, such as Foundayo or oral Wegovy |
These are discussion points, not medical recommendations. The right choice depends on your health history, and the new data make a strong case for not deciding alone.
The bigger picture
GLP-1 medications are increasingly understood as long-term treatments for chronic conditions, similar to blood pressure or cholesterol medications. "Health systems need plans in place to help people continue their medication indefinitely, recognizing that GLP-1s treat chronic conditions," Al-Aly said (ScienceDaily). That framing has real consequences for insurance coverage, pricing, and how patients think about starting treatment in the first place.
Frequently asked questions
Does stopping Ozempic or Mounjaro increase heart attack risk?
A large observational study in BMJ Medicine found that among veterans with type 2 diabetes, stopping GLP-1 medications was linked to higher risk of heart attack, stroke, and death: 14% higher after one year off and 22% higher after two years off, compared with continuous users.
How long do I need to stay on a GLP-1 for heart benefits?
In this study, people who stopped before 18 months showed no significant cardiovascular benefit compared with sulfonylureas. Continuous use for three years was linked to an 18% lower risk.
Does restarting a GLP-1 restore the benefit?
Partly. People who stopped and later restarted had an average 12% lower risk compared with sulfonylureas, versus 18% for continuous users.
Does this apply to people taking GLP-1s only for weight loss?
The study included only people with type 2 diabetes, so results may not apply directly. Other research shows weight, blood pressure, and cholesterol improvements tend to reverse after stopping in other groups too.
Should I stop my GLP-1 medication?
Do not stop or change your medication without talking to your prescriber. If cost or side effects are the issue, there are often solutions such as dose changes, savings programs, or switching to another option.
The bottom line
This study adds to growing evidence that GLP-1 medications work best as long-term treatment, and that the heart benefits fade after stopping. It is not a reason to panic, but it is a strong reason to plan any change with your prescriber and avoid long, unplanned gaps.
Sources
- ScienceDaily / Washington University: Stopping Ozempic may raise heart attack and stroke risk
- Axios: What happens when people stop GLP-1s
Educational content written by Rolando Valenzuela, founder of GLPTree. Not medical advice. Talk to your prescriber before starting, stopping, or switching any medication.